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CP 96,345 is a nonpeptide high affinity antagonist of the substance P (NK,) receptor. The radiosynthesis 
of [ “C]CP 96,345 suitable for Positron Emission Tomography (PET) applications is described. [ “C]CP 
96,345 was prepared by 0-methylation of a desmethyl precursor via in situ generation of its phenolate 
salt. The in uivo tissue distribution of [ “C]CP 96,345 in guinea pigs (n = 2) at 5 and 30 min was determined. 
Uptake was low in brain ( z 0.04% dose/g) and highest ( z l-2% dose/g) in the spleen and lungs. The 
present findings indicate that the use of [ “C]CP 96,345 in PET might be more applicable to the study 
of substance P receptors in peripheral tissues involved with inflammatory disease and arthritis. 
Introduction 
The compound CP 96,345 has recently been reported 
to be the first potent nonpeptide antagonist of sub- 
stance P (Lowe et al., 1991, 1992; McLean et al., 
1991; Snider et al., 1991). CP 96,345 binds stereo- 
selectively and with high affinity (& = 0.2 nM) 
to the substance P (NK-1) receptor (Lowe et al., 
1992; Snider et al., 1991). Radiolabeled CP 96,345 
has the potential for in vitro and in vivo localization 
of substance P receptor sites. Successful mapping 
of substance P receptor sites may yield useful 
diagnostic information in the study of arthritis, 
inflammatory diseases and carcinoid tumor (Payan, 
1989). A preliminary account of the characterization 
of substance P receptor sites in guinea pig brain 
using [)H]CP 96,345 (Lowe et al., 1991) has been 
published (McLean, 1991). The present work de- 
scribes the synthesis of carbon-l 1 analogue CP 96,345 
suitable for Positron Emission Tomography appli- 




[“C]CP 96,345, 3 (Fig. l), was prepared by reac- 
tion of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-hydroxy- 
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phenyl)methyl]-l-azabicyclo[2.2.2]-octan-3-amine, 2, 
with [“Clmethyl iodide. The desmethyl precursor 2 
was prepared from the previously reported optically 
active compound 1 (Lowe et al., 1992) by imine 
formation with salicylaldehyde (Fig. 1) followed by 
reduction with boranejmethyl sulfide. Compound 2 
(l-2 mg) was dissolved in 8-9 p L of 1 M tetrabutyl- 
ammonium hydroxide in methanol (Aldrich Chemi- 
cal Co.) in a septum-capped vial. The methanolic 
solution was evaporated under a gentle stream of 
nitrogen for l-2 h and the residue of phenolate salt 
was dissolved in 150-200 p L of dimethyl formamide. 
The [ “Clmethyl iodide was trapped in the solution at 
-40°C and the reaction mixture was subsequently 
heated at 85-90°C for 5 min. [“C]CP 96,345 was 
purified by reverse phase HPLC using a Waters 
Bondapak CN column (3.9 x 300 mm) eluted with 
ethanol/O.1 M ammonium acetate (1: 4). [ “C]CP 
96,345 eluted at 19-20min at a flow rate of 
2.3 mL/min. Radiochemical yields of 30-50% (decay 
corrected) were obtained in a total synthesis time 
of 4560min to 1 h from end-of-beam. Analytical 
HPLC of the HPLC purified 3 showed a high radio- 
chemical purity (< 95%) and a specific activity 
> 1000 Ci/mmol (end-of-synthesis). An authentic 
sample of CP 96,345 provided by Pfizer, was used as 
a reference standard. Radiochromatographic analysis 
was performed with a 4.6 x 250 mm Phenomenex 
Ultremex Cl8 IP using acetonitrile/O.l M ammonium 
acetate (95: 5, 3.0 mL/min) as solvent. 
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Table 1. Brain uptake of [ “C]CP 96,345 
in guinea pigs (n = 2) 
%Dose/g 
Tissue 5 min 30 min 
Striatum 0.053 0.048 
Cortex 0.038 0.046 
Cerebellum 0.038 0.048 
Hippocampus 0.032 0.045 
Hypothalmus 0.039 0.042 
Olfactory bulb 0.030 0.033 
Animal studies 
[ “C]CP 96,345 was formulated for animal injection 
by a nine-fold dilution of the HPLC purified product 
with physiologic saline. Guinea pigs were anesthe- 
sized with ether, administered 50-100 PCi via femoral 
vein injection of the above formulation and sacrificed 
at 5 and 30 min. Biodistribution data for two guinea 
pigs per each time point in the brain and peripheral 
tissues are given in Tables 1 and 2. 
Results and Discussion 
The chiral phenolic precursor 2 was prepared from 
the intermediate quinuclidine amine 1 (Lowe et al., 
: 
1992) (Fig. 1) via imine formation and borane/methyl 
S7 sulfide reduction. The radiosynthesis of [ “C]CP 
96,345 was readily accomplished by 0-methylation of 
2 via in situ generation of its phenolate salt using 
excess tetrabutylammonium hydroxide in dimethyl 
formamide. Co-injection of HPLC of the radio- 
labeled product along with authentic CP 96,345 gave a 
single radioactive peak (retention time = 19-22 min) 
coincident with the UV peak of [“C]CP 96,345. The 
highly lipophilic nature of [“C]CP 96,345 resulted 
in very long HPLC elution times using C-8 or C-18 
A columns which presented practical problems in 
product recovery and reformulation for animal stud- 
ies. The use of a Bondapak CN column made it 
possible to elute the product in a buffer-ethanol (4 : 1) 
solvent system which could be conveniently diluted 
for subsequent injection into guinea pigs. 
In uivo biodistribution of [ “C]CP 96,345 was per- 
formed in the guinea pig. This choice of animals 
model allowed a direct comparison between [3H]CP 
96,345 and [“C]CP 96,345 since in vitro results 
with the tritiated compounds have been published 
(McLean et al., 1991). Furthermore, the regional 
binding of substance P to substance P(NK-1) recep- 
tors have been studied in the guinea pig brain (Dam 
Table 2. Uptake of [ “C]CP 96,345 in 
peripheral tissues 
%Dose/g 
Tissue 5 min 30 min 
Left ventricle 0.45 0.19 
Left atrium 0.35 0.18 
Lung 1.78 2.06 
Liver 0.71 0.47 
Spleen 1.51 0.71 
Pancreas 0.35 0.27 
Blood 0.048 0.084 
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and Quirion, 1986). Biodistribution data for [ “C]CP 
96,345 in various brain tissues and peripheral tissues 
5 and 30 min post-injection (n = 2 guinea pigs) are 
summarized in Tables 1 and 2. Table 1 shows that the 
overall brain uptake of [ “C]CP 96,345 was minimal, 
~0.1% of the injected dose at 30 min. The distri- 
bution of activity was nearly uniform (~0.04% 
dose/g) and nonselective in various regions of the 
brain, including the striatum, cerebellum, cortex, 
hypothalmus, hippocampus and olfactory bulb. The 
calculated variances for brain regions (Table 1) were 
very small with a maximum value of 0.0002 for the 
olfactory bulb. Brain activity levels were slightly 
lower than blood activity and ~3 times lower than 
heart activity. Table 2 shows that highest peripheral 
accumulation of activity occurred in the spleen and 
lungs. For tissues in Table 1, the calculated variances 
were higher, ranging from 0.00006 to 0.670. 
Regional selective binding of both [ 3H]substance P 
(Dam and Quirion, 1986) and [3H]CP 96,345 (Lowe 
et al., 1991) to substance P receptors sites in the brain 
have been determined qualitatively. For example, 
qualitative autoradiographic studies of both [ ‘H]CP 
96,345 and [3H]substance P have indicated modest 
binding in the striatum, hippocampus and hypothal- 
mus and dense binding in the olfactory bulb. By 
contrast, Table 1 shows that the in vivo localization 
of [ “C]CP 96,345 was nearly identical in the striatum, 
cerebellum, cortex, hypothalmus, hippocampus and 
olfactory bulb. Since the calculated variances in 
Table 1 were very small, additional in vivo studies 
with larger groups of animals were not conducted. 
Based on the present preliminary evaluation of 
[ “C]CP 96,345, we conclude that CP 96,345 is unsuit- 
able as an in uivo marker of substance P receptors 
in the brain. HPLC data and log P measurements 
(log P = 4.5) indicate that the free base form of CP 
96,345, with its two highly basic nitrogens, may exist 
mostly in cationic form, either a monocation or 
possibly even a dication, thus precluding its passage 
through the blood-brain barrier. Alternative exper- 
iments for the low brain uptake, such as extensive 
binding to blood proteins, cannot be ruled out. 
PET studies with [“C]CP 96,345 might be more 
appropriately applied to the detection of substance 
P receptors in tissue regions of interest involved 
with inflammatory disease and arthritis (Payan, 
1989). Studies to determine the specific binding of 
[“C]CP 96,345 to various peripheral tissues and its 
applications in animal models of such diseases are 
underway. 
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